Ceram signs agreement with AstraZeneca

Published: 18-Jan-2013
Research & Development

Will develop controlled release technology for delivery of selected AZ compounds


Anglo-Swedish pharmaceutical manufacturer AstraZeneca has signed an agreement with Ceram Research in which Ceram will develop its inorganic-based controlled release technology in a feasibility study for the delivery of selected AstraZeneca compounds.

‘This technology, if successfully implemented, could provide AstraZeneca with an alternative formulation approach for delivering these compounds,’ said Tony Kinsella, CEO of Ceram, a materials development company headquartered in Stoke-on-Trent, Staffordshire, UK.

Controlled release technology is just one of the development projects that Ceram’s team of materials experts is currently working on; others include multi-element substituted hydroxyapatite for orthopaedic device coating applications.

  • Companies:
  • AstraZeneca
  • Lucideon
See more

You may also like

Drug Delivery

AstraZeneca and Amgen's Tezspire meets primary endpoints in Phase III trial

Read more
The Phase III WAYPOINT trial demonstrated Tezspire's ability to reduce nasal polyps and congestion compared to placebo when administered subcutaneously

Trending Articles

  1. BioPharmaSpec expands its biopharma discovery and preclinical capabilities with three new facilities The contract research organisation (CRO) has expanded its European presence with three facilities, which are catered for biopharmaceutical drug discovery and preclinical characterisation
  2. Efficient PFAS-free degassing of aqueous solutions New silicone-based degassing chamber eliminates the risk of PFAS contamination
  3. CDMO market trends and dynamics The rise of the embedded model
  4. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  5. Transmission Raman Spectroscopy - access the webinar series today Offering significant advantages for bulk, quantitative and non-destructive analysis, Transmission Raman Spectroscopy is a preferred choice for applications where surface analysis is insufficient or prone to errors. Speakers from Agilent, Novartis Pharma, AstraZeneca, Bristol-Myers Squibb and AbbVie go deeper in this FREE webinar series

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Drug Delivery

AstraZeneca and Amgen's Tezspire meets primary endpoints in Phase III trial

The Phase III WAYPOINT trial demonstrated Tezspire's ability to reduce nasal polyps and congestion compared to placebo when administered subcutaneously
Research & Development

AstraZeneca's asthma-targeting Airsupra meets primary endpoint in Phase III trial

The inhaled therapeutic has proven effective in reducing the risk of severe asthma attacks in patients with intermittent or persistent asthma
Drug Delivery

Aptamer and AstraZeneca to determine the efficacy of targeted siRNA delivery vehicle

AstraZeneca is providing Aptamer with siRNAs to test if its Optima fibrotic liver technology can successfully facilitate the delivery and cell integration of therapeutic RNA
Research & Development

BenevolentAI and AstraZeneca collaboration leads to novel lupus target discovery

The novel target will be added to AstraZeneca's drug development pipeline for lupus, an autoimmune disease with significant unmet needs in the patient population
Research & Development

AstraZeneca presents data at ATS 2024 highlighting tezepelumab’s potential in treating COPD

Late-breaking results from the Phase IIa COURSE trial provide insight into tezepelumab's impact on COPD exacerbations in patients with a broad range of eosinophil levels
Research & Development

BenevolentAI and AstraZeneca collaboration finds novel heart failure target

The heart failure target was discovered through an AI platform, with AstraZeneca then experimentally validating its clinical potential
Research & Development

COVID-19 still a significant risk for the immunocompromised, study finds

AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Subscribe now